PRPO logo.png
Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel
22 sept. 2020 10h30 HE | Precipio, Inc.
NEW HAVEN, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ AML (Acute Myeloid...